Tirzepatide does not appear on routine blood tests ordered in standard clinical practice, including complete blood counts, comprehensive metabolic panels, lipid panels, or hemoglobin A1c measurements
When comparing Wegovy injection vs oral alternatives, the injection remains the primary option for weight management due to its higher clinical effectiveness and FDA approval for obesity treatment
Nazar-Stewart V et al
We dont have much data yet, but one study from late in 2025, which compared tirzepatide to both transdermal (through the skin) testosterone and placebo, made an argument worth considering: Authors La Vignera & colleagues argued that tirzepatide may be effective in improving both metabolic parameters, ED, and gonadal hormone levels in patients with obesity and metabolic hypogonadism, also known as low testosterone levels
An analysis of FDA adverse event reports also found cases of male sexual dysfunction, including decreased libido, associated with GLP-1 receptor agonists like tirzepatide, though the overall reported risk is considered low
The theoretical considerations regarding IGF-1 and existing tumors represent precautionary monitoring parameters rather than documented side effects